Peptide Therapy Arizona: 2026 Legal Guide

Key facts at a glance

Several peptide medicines are FDA-approved for specific uses, including semaglutide and tirzepatide (GLP-1 medicines), tesamorelin (Egrifta), and bremelanotide (Vyleesi, formerly known as PT-141).
Compounded drugs, including compounded peptides, are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before they are marketed.
In September 2023, FDA placed BPC-157, TB-500, CJC-1295, ipamorelin, and other popular peptides in Category 2, its list of substances that may present significant safety risks in compounding.
In April 2026, those peptides were removed from Category 2 after their nominations were withdrawn. Removal is not the same as approval, and they were not placed in Category 1.
On July 23 and 24, 2026, an FDA advisory committee narrowly voted to recommend six peptides, including BPC-157, for the 503A bulks list. As of late September 2026, FDA has not begun or completed the rulemaking needed to make that official.
A 2025 systematic review of BPC-157 in orthopaedic medicine found 35 animal studies and only 1 human clinical study.
In Arizona, compounding pharmacies are regulated by the Arizona State Board of Pharmacy, which offers a public license verification tool.

Peptide therapy is everywhere right now, from podcasts to med spas across Scottsdale and Phoenix. Some peptides are well-studied, FDA-approved medicines. Others are sold online as research chemicals with almost no human safety data, and the federal rules changed several times in 2026 alone.

This guide separates what is approved, what is legally compoundable, and what is still unsettled, with dates and primary sources.

What is peptide therapy?

Peptides are short chains of amino acids, the same building blocks that make up proteins. Peptide therapy simply means using a peptide as a medicine, usually by injection, to act on a specific receptor or pathway in the body.

Insulin and GLP-1 medicines are peptides. So are many products marketed for recovery, sleep, or longevity that have never been through a human clinical trial. The word peptide tells you about chemistry, not proof.

Which peptides are FDA-approved and can doctors prescribe them?

Yes. Licensed prescribers can prescribe FDA-approved peptide medicines for their approved uses, and in some cases off-label when clinically appropriate. These products have gone through controlled trials and FDA review of safety, effectiveness, and manufacturing quality.

Peptide	FDA status	Approved use
Semaglutide, tirzepatide	FDA-approved (brand products)	Type 2 diabetes and chronic weight management, depending on the product
Tesamorelin (Egrifta SV)	FDA-approved, initial approval 2010	Reducing excess abdominal fat in adults with HIV-associated lipodystrophy; the label states it is not indicated for weight loss
Bremelanotide (Vyleesi), also called PT-141	FDA-approved, initial approval 2019	Acquired, generalized low sexual desire (HSDD) in premenopausal women; not approved for postmenopausal women or men
Sermorelin (formerly Geref)	Previously FDA-approved; brand discontinued	Geref is no longer marketed; FDA determined in 2013 it was not withdrawn for safety or effectiveness reasons

According to its FDA prescribing information, tesamorelin is approved only for a specific HIV-related condition, and its long-term cardiovascular safety has not been established. The Vyleesi label reports nausea in 40% of trial participants, and 13% needed anti-nausea medication.

Sermorelin has an unusual history. Geref was approved in 1990 and 1997, then discontinued by its manufacturer, with approvals withdrawn in 2009. In a 2013 Federal Register notice, FDA determined it was not withdrawn for reasons of safety or effectiveness. No FDA-approved sermorelin product is currently marketed, so any sermorelin available today is compounded.

GLP-1 medicines are the most widely used peptides in midlife care today. Our guide to GLP-1 weight loss in Arizona covers them in depth.

What are the 503A bulks list categories for peptides?

Most wellness peptides are not FDA-approved, so the only legal route to a patient is compounding. A 503A pharmacy can generally compound with a bulk ingredient only if it meets certain federal criteria, and FDA sorts nominated ingredients into three interim categories while it decides.

According to FDA’s 503A bulks page:

Category 1: under evaluation, and FDA does not intend to take action against compounders using them if conditions are met.
Category 2: raises significant safety risks in compounding. FDA may take enforcement action.
Category 3: not enough information to evaluate. Also not eligible for the Category 1 policy.

In September 2023, FDA moved more than a dozen peptides into Category 2, as described by the FDA Law Blog. FDA’s own Category 2 page recorded concerns such as immunogenicity risk and peptide-related impurities for BPC-157, and noted it had not identified any human exposure data for the TB-500 fragment.

Are peptides like BPC-157 legal in 2026?

As of late September 2026, BPC-157 and similar peptides are in a regulatory gray zone. They are no longer in Category 2, an FDA advisory committee has recommended some of them, but FDA has not yet formally added any of them to the 503A bulks list.

Here is the verified timeline:

February 27, 2026: HHS Secretary Robert F. Kennedy Jr. announced that most peptides on the Category 2 list would be moved, according to Pharmacy Times.
April 2026: Following an April 16 Federal Register notice, FDA removed 12 peptides from Category 2 because their original nominators withdrew them, as reported by Latham and Watkins. FDA now lists BPC-157, TB-500, CJC-1295, AOD-9604, and others as nominated but withdrawn.
May 14, 2026: GHK-Cu was re-added to FDA’s Category 1 list, but only for non-injectable routes. That means 503A pharmacies may compound topical forms under FDA’s interim policy, while injectable GHK-Cu is not covered.
July 23 and 24, 2026: The Pharmacy Compounding Advisory Committee reviewed seven peptides. BPC-157 (for ulcerative colitis), KPV, and TB-500 each passed 8 to 6, and MOTS-c passed 7 to 5, according to PharmExec. Semax and epitalon were recommended, and emideltide (DSIP) was not, per an analysis from the law firm McDermott.
September 2026: A September 17 legal analysis from Frier Levitt notes the votes are advisory and do not change legal status. As of September 27, 2026, FDA has not proposed a rule adding any of the six peptides, and none appears on its Category 1 list.

A second advisory meeting on GHK-Cu (injectable), LL-37, dihexa, melanotan II, and PEG-MGF is expected before the end of February 2027. Rules may change again, so ask your provider how any peptide is being sourced today.

How strong is the evidence for wellness peptides?

For most wellness peptides, the human evidence is thin. Promising animal studies are common, but well-designed human trials are rare, and that is the central issue your provider should discuss with you.

A 2025 systematic review in the HSS Journal of BPC-157 for musculoskeletal healing included 36 studies. Thirty-five were preclinical animal studies and one was a human clinical study. The authors noted the lack of human safety data.

At the July 2026 advisory meeting, FDA staff scientists highlighted a general lack of quality data supporting safety and effectiveness, according to ABC News. A favorable vote is a compounding decision, not proof that a peptide works.

Is it safe to buy research peptides online?

No. Peptides sold online as research chemicals or not for human use skip the prescriber, the pharmacist, and the quality controls that protect patients. The label does not make them legal to sell for human use, and it does not make them safe.

In a December 2024 warning letter, FDA told one seller that its research use only labeling did not change the fact that its website promoted the products for human therapeutic use, making them unapproved new drugs.

A 2024 analysis in Annals of Pharmacotherapy identified 40 websites selling semaglutide and tirzepatide for research purposes. Only 3 included a diluent, and none provided injection instructions. The authors also cited laboratory testing in which one sample showed elevated endotoxin and measured semaglutide content ran 29% to 39% above the label, which could lead to excessive dosing.

How do I choose a peptide therapy provider in Scottsdale or Arizona?

Choose a licensed prescriber who evaluates you first, sources only from licensed pharmacies, and is candid about evidence and legal status. If a clinic cannot tell you where your peptide comes from, that is your answer.

A licensed prescriber. An MD, DO, NP, or PA licensed in Arizona should review your history, medications, and goals before prescribing.
A licensed pharmacy. Ask whether the product is FDA-approved, from a state-licensed 503A pharmacy, or from an FDA-registered 503B outsourcing facility. FDA explains that 503B facilities follow current good manufacturing practice and are inspected by FDA, while 503A pharmacies are overseen mainly by state boards.
Baseline labs. A thoughtful plan starts with appropriate lab testing and a way to monitor you over time.
Real informed consent. You should hear the FDA status, the quality of the evidence, known risks, and alternatives, in plain language.
No guarantees. Be cautious of anyone promising specific results.

Who regulates compounding pharmacies in Arizona?

The Arizona State Board of Pharmacy licenses and regulates pharmacies in the state, and its website lets anyone verify an existing license or permit. That is a useful first check for any pharmacy filling a peptide prescription.

Arizona’s Current Good Compounding Practices rule (R4-23-410) requires ingredients that meet official compendium or other high-quality standards, labels that identify the product as compounded with a beyond-use date, and compounding records kept for at least seven years.

How does Amsara Health approach peptide therapy in Arizona?

Amsara Health is a concierge integrative telehealth practice based in Scottsdale, serving adults across Arizona. Our approach to peptides is evidence-first, and your provider will determine what, if anything, is appropriate for you.

We prescribe FDA-approved peptide medications. When appropriate, we also prescribe compounded medications from licensed 503A and 503B pharmacies, including GLP-1s and a topical facial cream with GHK-Cu and estradiol. We do not prescribe research-grade peptides, or peptides the FDA has not cleared for compounding, such as BPC-157 or TB-500.

Your first visit is a consultation and full history. Labs are ordered afterward, and your follow-up reviews results and builds your plan. For many people, the most useful starting point is not a peptide at all but a clear picture of metabolic, hormonal, and biological age markers. When a peptide is considered, your provider will explain its FDA status, the evidence behind it, and how it will be monitored. Care is led by clinicians such as Dr. Mia Chorney, DNP, FNP-BC, MSCP, our Cofounder and Chief Medical Officer.

Learn more about the tests we offer, GLP-1 care in Arizona, visit and membership pricing, and how to become a patient.

Frequently asked questions

Is BPC-157 FDA-approved?

No. BPC-157 is not an FDA-approved drug. It was removed from FDA Category 2 in April 2026, and an FDA advisory committee voted 8 to 6 in July 2026 to recommend it for the 503A bulks list for ulcerative colitis, but as of September 2026 FDA has not completed the rulemaking to add it.

Is PT-141 the same as bremelanotide?

Yes. PT-141 is the research name for bremelanotide, which is FDA-approved as Vyleesi for acquired, generalized low sexual desire in premenopausal women. It is not approved for postmenopausal women or men.

Are compounded peptides FDA-approved?

No. FDA states that compounded drugs are not FDA-approved, which means FDA does not verify their safety, effectiveness, or quality before they are marketed. Compounding can still be legal when it follows federal and state rules.

Can I get peptide therapy through telehealth in Arizona?

Yes, when a licensed Arizona provider evaluates you and determines a treatment is appropriate. Amsara Health serves adults 18 and older across Arizona by telehealth. It prescribes FDA-approved peptide medications and, when appropriate, compounded medications from licensed 503A and 503B pharmacies, and it does not prescribe research-grade peptides.

Why not just buy peptides online?

Products labeled for research use only bypass prescribers, pharmacists, and quality controls. FDA has issued warning letters to such sellers, and published analyses have found missing instructions, dosing that did not match the label, and possible contamination.

What does Category 2 mean for peptides?

Category 2 is FDA’s interim list of bulk substances that may present significant safety risks in compounding. Many popular peptides were placed there in September 2023 and removed in April 2026, but removal alone did not make them approved or place them in Category 1.

Curious how your body is aging before you consider any peptide? Start with our guide to biological age testing.

Sources

This article is for educational purposes and is not a substitute for individual medical advice. Talk with a licensed provider about your specific situation.

Want an evidence-first look at whether peptides fit your plan?

Unhurried appointments, advanced diagnostics, and a plan built for you.

Book Your FREE 15-Minute Discovery Call

Schedule Your Initial Visit

Already a patient? Visit your Amsara Patient Portal →

Peptide Therapy in Arizona: What Is Legal and Proven in 2026